Summit appoints Ralf Rosskamp as chief medical officer

Duchenne muscular dystrophy (DMD) specialist Summit Therapeutics (Nasdaq: SMMT) has appointed Ralf Rosskamp as chief medical officer.

Dr Rosskamp was most recently vice president of global clinical development at NPS Pharmaceuticals and oversaw the development of several rare disease drug candidates.

Glyn Edwards, chief executive of Summit, said: “Dr Rosskamp’s 25 years of drug development and regulatory expertise, especially his experience with rare and pediatric diseases, are a great fit with Summit and our clinical programs. He is joining at a really exciting time as we initiate Phase II trials in our utrophin modulator program for DMD and look forward to reporting data from our proof of concept Phase 2 trial of SMT19969 for CDI.  We welcome him to the team.”